Oncology Focus Position Galena Biopharma as a partner for targeted cancer therapeutics across mid to late-stage development, highlighting NeuVax immunotherapy and the potential to expand collaboration in combination regimens and supportive care.

Commercial Portfolio Leverage existing commercial drugs Abstral and Zuplenz to offer integrated oncology solutions, including pain and antiemetic management, creating co-promotion or bundled value propositions for oncology clinics.

Clinical Pipeline Identify opportunities around NeuVax in the Phase 3 program for potential licensing, co-development, or regional commercialization partnerships to accelerate time-to-market in key international markets.

Financial Levers Explore strategic partnerships or milestone-driven deals to align with Galena’s funding profile, offering investors alongside collaboration opportunities that mitigate risk while enabling clinical and commercial scale.

Operational Readiness Target mid-sized biopharma and specialty oncology distributors as distribution partners, given Galena’s scale (51-200 employees) and existing technology stack for efficient digital outreach and stakeholder engagement.